Peaks, Troughs, and Fluctuation: How Dosing Frequency Shapes the Swing

Reaching steady state does not mean your levels go flat. Even at the plateau, a compound rises to a peak shortly after each dose and drifts down to a trough just before the next one. The size of that swing — the fluctuation between peak and trough — is set by how often you dose relative to the half-life. It is a different question from how high the plateau sits or how much a compound accumulates, and it often matters more for how a protocol actually feels. You can see the swing narrow or widen as you change the interval in the Dose Interval Visualizer.

Peak, trough, and the ratio between them

Three points describe steady state within any interval: the peak (Cmax, just after dosing), the trough (Cmin, just before the next dose), and the average in between. Pharmacokinetic comparisons define fluctuation as the peak-to-trough ratio — the steady-state mean Cmax divided by the steady-state mean Cmin across the recommended dosing interval. A ratio near 1 means an almost flat line; a large ratio means levels spike after each dose and sag deeply before the next.

The relationship is clean, and it is the one the antipsychotic comparison below states directly: formulations with a shorter half-life show greater peak-to-trough fluctuation at an equivalent dosing interval. Dose often relative to how fast you clear and little falls off between doses, so the line stays smooth. Dose far apart and most of each dose clears before the next arrives, producing a wide swing.

At steady state, levels still rise to a peak after each dose and fall to a trough before the next — the peak-to-trough ratio measures that swing.

A handy anchor: a drug with a 24-hour half-life dosed once daily has a peak-to-trough ratio of about 2. That is arithmetic rather than a study finding. Elimination is first-order, so one half-life removes about half of what is there; when the dosing interval equals one half-life, the trough sits at about half the peak. The table below is the same calculation at other intervals — the ratio is 2 raised to the power of (interval ÷ half-life).

Dosing interval relative to half-life	Approx. peak-to-trough ratio	Character of the level
¼ half-life (very frequent)	~1.2	nearly flat
½ half-life	~1.4	gentle ripple
1 half-life	~2	modest swing
2 half-lives	~4	pronounced peaks and troughs
3+ half-lives (far apart)	~8+	spikes with deep troughs

Why the swing matters

Fluctuation is not just cosmetic — it maps onto real experience at both ends of each cycle.

• At the peak: many dose-related side effects track the highest level reached, not the average. A large swing means the peak overshoots the average considerably, so a schedule that looks reasonable “on average” can still deliver a rough peak. The evidence here is suggestive rather than settled. The review comparing long-acting injectable antipsychotics with their oral equivalents puts it carefully: most of the literature supports a link between large peak-to-trough swings and increased adverse events, but some studies do not show that relationship, and its argument that flatter plasma levels should mean flatter receptor occupancy is reasoning from mechanism, not a measured outcome.
• At the trough: a deep trough can drop levels below the effective range before the next dose, so the compound’s effect wanes late in the interval. With big swings you can be over-exposed early and under-exposed late within the same cycle.

This is the core reason smoother is often better: it keeps you inside the useful window — above the effective level, below the level that provokes side effects — for more of the interval. Long-acting formulations and long-half-life drugs are frequently designed specifically to shrink the swing.

Fluctuation vs. accumulation — not the same thing

It is easy to conflate the two, but they answer different questions:

• Accumulation (covered in Drug Accumulation) is how much higher the steady-state plateau sits versus a single dose.
• Fluctuation is how much levels swing within each interval once you are at that plateau.

The same lever — half-life relative to interval — drives both, in the same direction: frequent dosing (relative to half-life) means more accumulation and less fluctuation. So a heavily accumulating regimen is typically also a smooth one, and a barely-accumulating regimen (doses far apart) is typically a spiky one with deep troughs. But they remain distinct numbers, and the visualizer reports the peak, the trough, and the accumulation ratio separately so you do not have to infer one from the other.

Where GLP-1s land

Weekly GLP-1s illustrate the smooth end. Semaglutide’s prescribing information gives an elimination half-life of approximately one week; dosed once weekly, that puts the interval near one half-life, so the peak-to-trough swing is modest and levels ride relatively steadily across the week. That smoothness is part of why weekly dosing is tolerable and why missing a single dose does not immediately crater levels — the trough is not far below the peak to begin with. The flip side: any change is felt over the whole slow cycle, which is why titration works with the kinetics rather than against them. If you do miss a dose, the modest swing is why timing has some forgiveness — see Missed a GLP-1 Dose.

The takeaway

At steady state your levels still rise and fall each interval, and the size of that swing is governed by half-life versus dosing frequency. Dose often relative to how fast you clear and the line flattens; dose far apart and you get sharp peaks with deep troughs. Because side effects often track the peak and loss of effect tracks the trough, a smaller swing usually means steadier effects and better tolerability — which is exactly what long-half-life drugs and long-acting formulations are built to deliver.

Watch the peak-to-trough swing widen and narrow as you adjust the interval in the Dose Interval Visualizer, and use the Peptide Half-Life Visualizer to see the decay that shapes each trough.

This article is educational and not medical advice. Many research peptides are not approved for human use; dosing decisions belong with a qualified clinician.

Sources

• Comparison of the Peak-to-trough Fluctuation of Long-acting Injectable Antipsychotics and Their Oral Equivalents (Innovations in Clinical Neuroscience, 2012 — PMC) — defines peak-to-trough fluctuation as steady-state mean Cmax divided by steady-state mean Cmin over the recommended dosing interval; “Formulations with a shorter half-life (t1/2) will have greater peak-to-trough fluctuations, given an equivalent dosing interval”; and on the mixed literature linking large fluctuation to adverse events
• Elimination Half-Life of Drugs — StatPearls (NCBI Bookshelf) — on first-order elimination, the ~50%-per-half-life decay the ratio table is derived from, and steady state after four to five half-lives
• OZEMPIC (semaglutide) injection — FDA prescribing information, via DailyMed — “With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 weeks after the last dose”; steady state after 4 to 5 weeks of once-weekly administration